"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","EXSCEL 2017",2017,0,0,0,0,195,1557,0,0,200,1620,0,0,31.334522,1.014451,0.843471,1.22009,"","Low risk","<p>Quote: ""An interactive voice-response system assigned patients on the basis of computer generated block randomization.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: The rates of non-completers were 262/7356 (3.6%) and 303/7396 (4.1%) for exenatide group and placebo group, respectively. The rate and cause of adverse events leading to discontinuation of study drugs were almost the same between the groups (43.0% and 45.2% for exenatide group and placebo group, respectively). ITT was performed</p>","Low risk","<p>Quote: ""The events which constitute the principal endpoints of this trial will be adjudicated by the Clinical Events Classification Committee (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a coordinator.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias</b> for all domains for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,0,0,0,0,144,1116,0,0,178,1042,0,0,28.107151,0.755346,0.616694,0.925172,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at low risk of bias for all domains<b> </b>for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,4,140,0,0,1,137,0,0,0.403621,3.914286,0.443092,34.578897,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.21969416271073,0,0,1,163,0,0,1,161,0,1.48765385055062,0.251444,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","Dialysis (HD/PD)","SUBGROUP_AND_OVERALL","Idorn 2013",2013,0,0,0,0,0,14,0,0,0,10,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: “Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer-generated randomisation list provided by Novo Nordisk”.</p>","Low risk","<p>Quote: “Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”.</p>","High risk","<p>Comment: &gt;5% lost to follow up with discrepancies between groups.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be <b>at high risk</b> of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,2,151,0,0,0,20,0,0,0.213171,0.690789,0.034328,13.901029,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,1,30,0,0,0.258483,1,0.065532,15.25976,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","EXSCEL 2017",2017,0,0.0740151983038937,0,0,302,5769,0,0,382,5745,0,0.0054782495799647,39.431608,0.787287,0.680048,0.911437,"","Low risk","<p>Quote: ""An interactive voice-response system assigned patients on the basis of computer generated block randomization.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: The rates of non-completers were 262/7356 (3.6%) and 303/7396 (4.1%) for exenatide group and placebo group, respectively. The rate and cause of adverse events leading to discontinuation of study drugs were almost the same between the groups (43.0% and 45.2% for exenatide group and placebo group, respectively). ITT was performed</p>","Low risk","<p>Quote: ""The events which constitute the principal endpoints of this trial will be adjudicated by the Clinical Events Classification Committee (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a coordinator.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias</b> for all domains for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
1,3,"Cardiovascular death","CKD stages 1-2","SUBGROUP_AND_OVERALL","EXSCEL 2017",2017,0,0,0,0,200,5769,0,0,255,5745,0,0,37.968827,0.781051,0.65142,0.936479,"","Low risk","<p>Quote: ""An interactive voice-response system assigned patients on the basis of computer generated block randomization.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: The rates of non-completers were 262/7356(3.6%) and 303/7396(4.1%) for exenatide group and placebo group, respectively. The rate and cause of adverse events leading to discontinuation of study drugs were almost the same between the groups (43.0% and 45.2% for exenatide group and placebo group, respectively). ITT was performed.</p>","Low risk","<p>Quote: ""The events which constitute the principal endpoints of this trial will be adjudicated by the Clinical Events Classification Committee (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a coordinator.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at low risk of bias for all domains for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","EXSCEL 2017",2017,0,0,0,0,133,1557,0,0,126,1620,0,0,32.337941,1.098266,0.869541,1.387154,"","Low risk","<p>Quote: ""An interactive voice-response system assigned patients on the basis of computer generated block randomization.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: The rates of non-completers were 262/7356(3.6%) and 303/7396(4.1%) for exenatide group and placebo group, respectively. The rate and cause of adverse events leading to discontinuation of study drugs were almost the same between the groups (43.0% and 45.2% for exenatide group and placebo group, respectively). ITT was performed.</p>","Low risk","<p>Quote: ""The events which constitute the principal endpoints of this trial will be adjudicated by the Clinical Events Classification Committee (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a coordinator.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at low risk of bias for all domains for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,0,0,0,0,80,1116,0,0,109,1042,0,0,28.160729,0.685278,0.520039,0.903021,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,1,140,0,0,0,137,0,0,0.458068,2.93617,0.120647,71.457116,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,0,0,0,1,163,0,0,1,161,0,0,0.609441,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,1,151,0,0,0,20,0,0,0.464994,0.414474,0.017446,9.847032,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,3,"Cardiovascular death","Dialysis (HD/PD)","SUBGROUP_AND_OVERALL","Idorn 2013",2013,0,0,0,0,0,14,0,0,0,10,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: “Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer-generated randomisation list provided by Novo Nordisk”.</p>","Low risk","<p>Quote: “Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”.</p>","High risk","<p>Comment: &gt;5% lost to follow up with discrepancies between groups.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be <b>at high risk</b> of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
1,8,"4-point MACE (Hazard ratio)","CKD stages 1-2","SUBGROUP_AND_OVERALL","LEADER 2017",2017,-0.1208,0.0717,0,0,0,0,0,0,0,0,0,0,39.634914,0.886211,0.770027,1.019925,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
1,8,"4-point MACE (Hazard ratio)","CKD stages 3-5","SUBGROUP_AND_OVERALL","ELIXA 2018",2018,0.009,0.12,0,0,0,0,0,0,0,0,0,0,25.307228,1.009041,0.797562,1.276594,"","Low risk","<p>Quote: ""The randomised treatment kit number list will be generated centrally by Sanofi. The Investigational Product (IP) (lixisenatide or placebo) will be packaged in accordance with this list."" […] ""The Supply Chain Trial Manager (SCTM) will provide the randomized treatment kit number list and the Study Biostatistician will provide the randomisation scheme to the centralized treatment allocation system. Then, this centralised treatment allocation system will generate the patient randomisation list according to which it will allocate the treatments to the patients."" ""Two types of centralized treatment allocation system will be used, the Interactive Voice Response System (IVRS) and the Interactive Web Response System (IWRS) depending on the choice of the site.""</p>","Low risk","<p>Quote: ""Lixisenatide and placebo were indistinguishable. Patients, study staff, and individuals involved in analysis of trial data were masked to treatment allocation.”</p>","Low risk","<p>Comment: The rates of discontinuation were 105/3034 (3.5%) and 110/3034 (3.6%) for lixisenatide group and placebo group, respectively. The rate of adverse events leading to discontinuation of study drugs were 20.6% and 22.1% for lixisenatide group and placebo group, respectively. ITT was performed.</p>","Low risk","<p>Quote: ""Separate independent committees whose members were unaware of the study group assignments adjudicated potential cardiovascular, pancreatic, and allergic events.""</p>","Low risk","<p>Quote: ""Separate independent committees whose members were unaware of the study group assignments adjudicated potential cardiovascular, pancreatic, and allergic events.""</p>","Low risk","<p>The study is judged to be at <b>low risk </b>of bias for all domains<b> </b>for this result. </p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
1,8,"4-point MACE (Hazard ratio)","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,-0.2949,0.0853,0,0,0,0,0,0,0,0,0,0,35.057858,0.744606,0.629969,0.880104,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
1,12,"Composite kidney outcome (Hazard ratio)","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,-0.174353,0.137819,0,0,0,0,0,0,0,0,0,0.023716,30.983237,0.84,0.641162,1.100503,"Difined as doubling of serum creatinine or renal replacement therapy.","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
1,12,"Composite kidney outcome (Hazard ratio)","CKD stages 3-5","SUBGROUP_AND_OVERALL","REWIND 2019",2019,-0.128,0.093,0,0,0,1081,0,0,0,1118,0,0,40.83471,0.879853,0.733244,1.055777,"Defined as the development of macroalbuminuria (development of UACR >33·9 mg/mmol in people with a lower baseline concentration), a sustained 30% or greater decline in eGFR (ie, based on two consecutive eGFR concentrations), or new chronic renal replacement therapy comprising dialysis or renal transplantation.","Low risk","<p>Quote: ""Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site.""</p>","Low risk","<p>Quote: ""All investigators and participants were masked to treatment allocation.""</p>","Low risk","<p>Comment: overall, 17/4949 of dulaglutide group and 17/4952 of placebo group did not complete the study. The rates (9.1% [451/4949] and 6.3% [310/4952] for dulaglutide and placebo, respectively). Incidences of adverse events were almost the same between the groups. ITT was performed</p>","Low risk","<p>Quote: ""An independent clinical endpoint committee (CEC) will adjudicate CV events, pancreatitis events, thyroid evaluations that result in a biopsy or thyroidectomy, and all deaths.""</p>","Low risk","<p>Comment: all prespecified and key outcomes were reported</p>","Low risk","<p>The study is judged to be at <b>low risk </b>of bias for all domains<b> </b>for this result. </p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
1,12,"Composite kidney outcome (Hazard ratio)","CKD stages 1-2","SUBGROUP_AND_OVERALL","LEADER 2017",2017,-0.5221,0.1525,0,0,0,0,0,0,0,0,0,0,28.182053,0.593273,0.439994,0.79995,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
1,14,"Severe hypoglycaemia (Hazard ratio)","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,-0.4691,0.1912,0,0,0,0,0,0,0,0,0,0,100,0.625565,0.430054,0.90996,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
1,18,"Myocardial infarction (undefined)","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,0,0,0,0,83,1116,0,0,103,1042,0,0,99.255259,0.752392,0.570642,0.99203,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","18::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.301228858230932,-0.00714010261436958,-0.601319633243049,-0.00113808321881365,-0.0379808901360491,0.02370068490731,TRUE,TRUE
1,18,"Myocardial infarction (undefined)","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,1.40909824809491,0,0,1,140,0,0,0,137,0,1.98555787278415,0.744741,2.93617,0.120647,71.457116,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","18::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.301228858230932,-0.00714010261436958,-0.601319633243049,-0.00113808321881365,-0.0379808901360491,0.02370068490731,TRUE,TRUE
1,21,"Nonfatal stroke","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,0,0,0,0,31,1116,0,0,55,1042,0,0,100,0.526263,0.341651,0.81063,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: Overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed.</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias for all domains </b>for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","21::overall","CD015849_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.438310890658298,-0.0242787863110203,-1.19291324036053,0.316291459043933,-0.0408005961606757,-0.00775697646136494,FALSE,FALSE
1,27,"Heart failure","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,1.62859697017817,0,0,1,140,0,0,0,137,0,2.65232809127351,100,2.93617,0.120647,71.457116,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","27::overall","CD015849_pub2_data","significance_only",TRUE,FALSE,TRUE,1.1883611858538,0.0076494271155772,-0.990726500084882,3.36744887179247,0.000175361580958749,0.0151234926501957,TRUE,FALSE
1,41,"Hypoglycaemia","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,1.42111214536066,0,0,29,140,0,0,36,137,0,2.01955972969159,57.322556,0.788294,0.513514,1.210107,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","41::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,0.083974637678506,-0.00234935526565699,-0.96300497636096,1.13095425171797,-0.0659903848740268,0.0612916743427128,TRUE,FALSE
1,41,"Hypoglycaemia","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.44671792600111,0,0,9,163,0,0,3,161,0,2.09299275741295,29.588585,2.96319,0.817013,10.747066,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","41::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,0.083974637678506,-0.00234935526565699,-0.96300497636096,1.13095425171797,-0.0659903848740268,0.0612916743427128,TRUE,FALSE
1,41,"Hypoglycaemia","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,2,30,0,0,13.08886,0.5,0.047851,5.224499,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","41::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,0.083974637678506,-0.00234935526565699,-0.96300497636096,1.13095425171797,-0.0659903848740268,0.0612916743427128,TRUE,FALSE
2,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Liu 2022",2022,0,0,0,0,0,42,0,0,0,42,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Sequence generation and allocation concealment methods were not reported in sufficient detail to permit judgement. There was no imbalance between</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. Clinically-relevant outcomes that would be expected for this type of intervention were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
2,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Neff 2016",2016,0,0,0,0,0,10,0,0,1,10,0,0,100,0.333333,0.015174,7.322544,"","Some concerns","<p>Comment: Sequence generation and allocation concealment methods were not reported in sufficient detail to permit judgement. No information on imbalance between groups were reported.</p>","High risk","<p>Quote: ""Open-label"".</p>","High risk","<p>Comment: 10/10 participants in the treatment group 1 and 8/10 participants in the treatment group 2 completed the study.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. Clinically-relevant outcomes that would be expected for this type of intervention were not reported.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
2,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Zhou 2019a",2019,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported.</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise <b>some concerns</b> in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
2,3,"Urinary albumin-creatinine ratio [mg/g]","CKD stages 1-2","SUBGROUP_AND_OVERALL","Zhou 2019a",2019,0,0,81.57,18.35,0,40,98.84,17.86,0,40,0,0,100,-17.27,-25.205447,-9.334553,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported.</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise <b>some concerns</b> in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
2,8,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Neff 2016",2016,0,1.57634021862302,0,0,0,10,0,0,0,10,0,2.48484848484848,NA,NA,NA,NA,"","Some concerns","<p>Comment: Sequence generation and allocation concealment methods were not reported in sufficient detail to permit judgement. No information on imbalance between groups were reported.</p>","High risk","<p>Quote: ""Open-label"".</p>","High risk","<p>Comment: 10/10 participants in the treatment group 1 and 8/10 participants in the treatment group 2 completed the study.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. Clinically-relevant outcomes that would be expected for this type of intervention were not reported.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
2,12,"Change in HbA1c [%]","CKD stages 1-2","SUBGROUP_AND_OVERALL","Zhou 2019a",2019,0.22,0.051,0,0,0,0,0,0,0,0,0,0.0026009999999999,100,0.22,0.120042,0.319958,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported.</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise <b>some concerns</b> in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
3,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Leiter 2014",2014,0,0,0,0,4,249,0,0,4,246,0,0,100,0.987952,0.249879,3.906091,"","Low risk","<p>Quote: “An interactive voice response system was used for the blinded randomisation, which was based on a sequestered fixed randomisation schedule.”</p>","Low risk","<p>Quote: “Double-blind.”</p>","High risk","<p>Comment: The ratios of discontinuation were almost balanced between the groups (68/253 [26.9%] in the sitagliptin group and 51/254 [20.1%] in the albiglutide group). The rate of withdrawal was nearly twice in the sitagliptin group (10.3%) compared to the albiglutide group (4.7%).</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results. However, the majority of data were reported at 26 weeks only, according to the protocol.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
3,3,"Severe hypoglycaemia","All CKD stages","SUBGROUP_AND_OVERALL","Leiter 2014",2014,0,1.00874175125926,0,0,1,249,0,0,4,246,0,1.01755992073359,100,0.246988,0.027803,2.194153,"","Low risk","<p>Quote: “An interactive voice response system was used for the blinded randomisation, which was based on a sequestered fixed randomisation schedule.”</p>","Low risk","<p>Quote: “Double-blind.”</p>","High risk","<p>Comment: The ratios of discontinuation were almost balanced between the groups (68/253 [26.9%] in the sitagliptin group and 51/254 [20.1%] in the albiglutide group). The rate of withdrawal was nearly twice in the sitagliptin group (10.3%) compared to the albiglutide group (4.7%).</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results. However, the majority of data were reported at 26 weeks only, according to the protocol.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
3,8,"HbA1c [%]","CKD stages 3-5","SUBGROUP_AND_OVERALL","Leiter 2014",2014,0,0.146240716896672,7.31,1.07,0,117,7.88,1.18,0,114,0,0.0213863472784525,46.449467,-0.57,-0.860706,-0.279294,"","Low risk","<p>Quote: “An interactive voice response system was used for the blinded randomisation, which was based on a sequestered fixed randomisation schedule.”</p>","Low risk","<p>Quote: “Double-blind.”</p>","High risk","<p>Comment: The ratios of discontinuation were almost balanced between the groups (68/253 [26.9%] in the sitagliptin group and 51/254 [20.1%] in the albiglutide group). The rate of withdrawal was nearly twice in the sitagliptin group (10.3%) compared to the albiglutide group (4.7%).</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results. However, the majority of data were reported at 26 weeks only, according to the protocol.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
3,8,"HbA1c [%]","CKD stages 1-2","SUBGROUP_AND_OVERALL","Leiter 2014",2014,0,0.112371148213497,7.23,0.887,0,125,7.5,1.066,0,122,0,0.0126272749508196,53.550533,-0.27,-0.514866,-0.025134,"","Low risk","<p>Quote: “An interactive voice response system was used for the blinded randomisation, which was based on a sequestered fixed randomisation schedule.”</p>","Low risk","<p>Quote: “Double-blind.”</p>","High risk","<p>Comment: The ratios of discontinuation were almost balanced between the groups (68/253 [26.9%] in the sitagliptin group and 51/254 [20.1%] in the albiglutide group). The rate of withdrawal was nearly twice in the sitagliptin group (10.3%) compared to the albiglutide group (4.7%).</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results. However, the majority of data were reported at 26 weeks only, according to the protocol.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
4,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","AWARD-7 2017",2017,0,0,0,0,9,382,0,0,6,194,0,0,100,0.76178,0.275124,2.109266,"","Low risk","<p>Quote: ""Participants were randomly assigned (1:1:1) by use of a computer­-generated random sequence with an interactive response system.""</p>","High risk","<p>Quote: ""An open­-label study with respect to assignment to dulaglutide or insulin, but with the investigators and patients masked to the dose of dulaglutide.""</p>","Low risk","<p>Comment: ITT was performed. All but one participant in dulaglutide 1.5 mg group were included in the safety analyses. Less than 5% of participants were excluded from the ITT. Reason for discontinuation were provided and were quite high in all groups.</p>","Low risk","<p>Quote: ""Death and cardiovascular, pancreatitis, and kidney events were prospectively adjudicated by an independent clinical endpoint committee on the basis of a prespecified adjudication process (adjudication committee members were masked to treatment assignments).""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
4,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","AWARD-7 2017",2017,0,0,0,0,8,382,0,0,4,194,0,0,100,1.015707,0.309704,3.331122,"","Low risk","<p>Quote: ""Participants were randomly assigned (1:1:1) by use of a computer­-generated random sequence with an interactive response system.""</p>","High risk","<p>Quote: ""An open-­label study with respect to assignment to dulaglutide or insulin, but with the investigators and patients masked to the dose of dulaglutide.""</p>","Low risk","<p>Comment: ITT was performed. All but one participant in dulaglutide 1.5 mg group were included in the safety analyses. Less than 5% of participants were excluded from the ITT. Reason for discontinuation were provided and were quite high in all groups.</p>","Low risk","<p>Quote: ""Death and cardiovascular, pancreatitis, and kidney events were prospectively adjudicated by an independent clinical endpoint committee on the basis of a prespecified adjudication process (adjudication committee members were masked to treatment assignments).""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
4,8,"Heart failure","CKD stages 3-5","SUBGROUP_AND_OVERALL","AWARD-7 2017",2017,0,1.6306218125246,0,0,1,382,0,0,0,194,0,2.65892749548102,100,1.527415,0.062513,37.32028,"","Low risk","<p>Quote: ""Participants were randomly assigned (1:1:1) by use of a computer­-generated random sequence with an interactive response system.""</p>","High risk","<p>Quote: ""An open­-label study with respect to assignment to dulaglutide or insulin, but with the investigators and patients masked to the dose of dulaglutide.""</p>","Low risk","<p>Comment: ITT was performed. All but one participant in dulaglutide 1.5 mg group were included in the safety analyses. Less than 5% of participants were excluded from the ITT. Reason for discontinuation were provided and were quite high in all groups.</p>","Low risk","<p>Quote: ""Death and cardiovascular, pancreatitis, and kidney events were prospectively adjudicated by an independent clinical endpoint committee on the basis of a prespecified adjudication process (adjudication committee members were masked to treatment assignments).""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
4,12,"Change in creatinine clearance [mL/min]","CKD stages 3-5","SUBGROUP_AND_OVERALL","AWARD-7 2017",2017,0,0,-1.2,2.8,0,382,-2.4,7.8,0,194,0,0,100,1.2,0.06706,2.33294,"","Low risk","<p>Quote: ""Participants were randomly assigned (1:1:1) by use of a computer­-generated random sequence with an interactive response system.""</p>","High risk","<p>Quote: ""An open­-label study with respect to assignment to dulaglutide or insulin, but with the investigators and patients masked to the dose of dulaglutide.""</p>","Low risk","<p>Comment: ITT was performed. All but one participant in dulaglutide 1.5 mg group were included in the safety analyses. Less than 5% of participants were excluded from the ITT. Reason for discontinuation were provided and were quite high in all groups.</p>","Low risk","<p>Quote: ""Death and cardiovascular, pancreatitis, and kidney events were prospectively adjudicated by an independent clinical endpoint committee on the basis of a prespecified adjudication process (adjudication committee members were masked to treatment assignments).""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
4,14,"Urinary albumin-creatinine ratio [mg/g]","All CKD stages","SUBGROUP_AND_OVERALL","Wang 2020a",2020,0,0,798.12,269.05,0,43,1405.93,276.87,0,38,0,0,100,-607.81,-727.041699,-488.578301,"","Low risk","<p>Quote: ""Based on randomized (1:1), open-label, parallel-group, controlled study design, a block randomisation method was applied in this study."" ""To prevent selection bias, we developed an allocation concealment mechanism, whereby the allocation sequence was maintained by a researcher who did not participate in the clinical work."" No imbalance between treatment groups were apparent.</p>","High risk","<p>Quote: ""Open-label study"".</p>","High risk","<p>Quote: ""Individuals were screened and 92 individuals were randomized and allocated to 2 groups (46 individuals per group). Eleven patients were excluded from the effective analysis due to missing follow-up data after randomisation. Eight patients discontinued IP: premature intervention discontinued due to AE (N = 6), withdrawal of consent (N = 1), and lost to follow-up (N = 1). These 8 patients were included in the FAS analysis but not in the PPS analysis.Eighty-one (88.0%) patients (43 in the intervention group, 38 in the control group) in total were included for the FAS analysis and 73 (79.3%) (37 patients in the intervention group, 36 patients in the control group) patients were included in the PPS.""</p><p>Comment: Fig 1 showed that 43/46 participants in the treatment group and 38/46 participants in the control group were included into the FAS analysis. 37/46 participants in the treatment group and 36/46 participants in the control group were included into the PPS analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
4,18,"Change in body weight [kg]","CKD stages 3-5","SUBGROUP_AND_OVERALL","AWARD-7 2017",2017,-3.8,0.51,0,0,0,382,0,0,0,194,0,0,100,-3.8,-4.799582,-2.800418,"","Low risk","<p>Quote: ""Participants were randomly assigned (1:1:1) by use of a computer­-generated random sequence with an interactive response system.""</p>","High risk","<p>Quote: ""An open­-label study with respect to assignment to dulaglutide or insulin, but with the investigators and patients masked to the dose of dulaglutide.""</p>","Low risk","<p>Comment: ITT was performed. All but one participant in dulaglutide 1.5 mg group were included in the safety analyses. Less than 5% of participants were excluded from the ITT. Reason for discontinuation were provided and were quite high in all groups.</p>","Low risk","<p>Quote: ""Death and cardiovascular, pancreatitis, and kidney events were prospectively adjudicated by an independent clinical endpoint committee on the basis of a prespecified adjudication process (adjudication committee members were masked to treatment assignments).""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be at <b>high risk of bias </b>in at least one domain for this result.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","18::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.301228858230932,-0.00714010261436958,-0.601319633243049,-0.00113808321881365,-0.0379808901360491,0.02370068490731,TRUE,TRUE
4,21,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Wang 2020a",2020,0,0.416159111154738,0,0,6,46,0,0,5,46,0,0.173188405797101,100,1.2,0.3938,3.656676,"","Low risk","<p>Quote: ""Based on randomized (1:1), open-label, parallel-group, controlled study design, a block randomisation method was applied in this study."" ""To prevent selection bias, we developed an allocation concealment mechanism, whereby the allocation sequence was maintained by a researcher who did not participate in the clinical work."" No imbalance between treatment groups were apparent.</p>","High risk","<p>Quote: ""Open-label study"".</p>","High risk","<p>Quote: ""Individuals were screened and 92 individuals were randomized and allocated to 2 groups (46 individuals per group). Eleven patients were excluded from the effective analysis due to missing follow-up data after randomisation. Eight patients discontinued IP: premature intervention discontinued due to AE (N = 6), withdrawal of consent (N = 1), and lost to follow-up (N = 1). These 8 patients were included in the FAS analysis but not in the PPS analysis.Eighty-one (88.0%) patients (43 in the intervention group, 38 in the control group) in total were included for the FAS analysis and 73 (79.3%) (37 patients in the intervention group, 36 patients in the control group) patients were included in the PPS.""</p><p>Comment: Fig 1 showed that 43/46 participants in the treatment group and 38/46 participants in the control group were included into the FAS analysis. 37/46 participants in the treatment group and 36/46 participants in the control group were included into the PPS analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","21::overall","CD015849_pub2_data","significance_only",TRUE,FALSE,TRUE,-0.438310890658298,-0.0242787863110203,-1.19291324036053,0.316291459043933,-0.0408005961606757,-0.00775697646136494,FALSE,FALSE
4,27,"Ischaemic stroke","CKD stages 3-5","SUBGROUP_AND_OVERALL","AWARD-7 2017",2017,0,0,0,0,3,382,0,0,0,194,0,0,100,3.563969,0.18502,68.651362,"","Low risk","<p>Quote: ""Participants were randomly assigned (1:1:1) by use of a computer­-generated random sequence with an interactive response system.""</p>","High risk","<p>Quote: ""An open­-label study with respect to assignment to dulaglutide or insulin, but with the investigators and patients masked to the dose of dulaglutide.""</p>","Low risk","<p>Comment: ITT was performed. All but one participant in dulaglutide 1.5 mg group were included in the safety analyses. Less than 5% of participants were excluded from the ITT. Reason for discontinuation were provided and were quite high in all groups.</p>","Low risk","<p>Quote: ""Death and cardiovascular, pancreatitis, and kidney events were prospectively adjudicated by an independent clinical endpoint committee on the basis of a prespecified adjudication process (adjudication committee members were masked to treatment assignments).""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be at high risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","27::overall","CD015849_pub2_data","significance_only",TRUE,FALSE,TRUE,1.1883611858538,0.0076494271155772,-0.990726500084882,3.36744887179247,0.000175361580958749,0.0151234926501957,TRUE,FALSE
5,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
5,3,"Withdrawal due to adverse events","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
6,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,1.42436820356945,0,0,0,45,0,0,2,151,0,2.02882477933965,100,0.66087,0.032303,13.520376,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
6,3,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0.415735412841381,0,0,7,45,0,0,17,151,0,0.172835933490394,100,1.381699,0.611701,3.12096,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
8,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","EXSCEL 2017",2017,0,0,0,0,195,1557,0,0,200,1620,0,0,31.334522,1.014451,0.843471,1.22009,"","Low risk","<p>Quote: ""An interactive voice-response system assigned patients on the basis of computer generated block randomization.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: The rates of non-completers were 262/7356 (3.6%) and 303/7396 (4.1%) for exenatide group and placebo group, respectively. The rate and cause of adverse events leading to discontinuation of study drugs were almost the same between the groups (43.0% and 45.2% for exenatide group and placebo group, respectively). ITT was performed</p>","Low risk","<p>Quote: ""The events which constitute the principal endpoints of this trial will be adjudicated by the Clinical Events Classification Committee (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a coordinator.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias</b> for all domains for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LEADER 2017",2017,0,0,0,0,144,1116,0,0,178,1042,0,0,28.107151,0.755346,0.616694,0.925172,"","Low risk","<p>Quote: ""A randomisation session will be carried out for all subjects by using the Interactive Voice/Web Response System.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: overall, 139/4668 (3.0%) of the liraglutide group and 159/4672 (3.4%) of the control group did not complete the study. ITT was performed</p>","Low risk","<p>Quote: ""External Event Adjudication Committees (EAC) will be constituted for the trial to perform ongoing adjudication of the below events in an independent and blinded manner.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at low risk of bias for all domains<b> </b>for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,4,140,0,0,1,137,0,0,0.403621,3.914286,0.443092,34.578897,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.21969416271073,0,0,1,163,0,0,1,161,0,1.48765385055062,0.251444,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,2,151,0,0,0,20,0,0,0.213171,0.690789,0.034328,13.901029,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,1,30,0,0,0.258483,1,0.065532,15.25976,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","EXSCEL 2017",2017,0,0.0740151983038937,0,0,302,5769,0,0,382,5745,0,0.0054782495799647,39.431608,0.787287,0.680048,0.911437,"","Low risk","<p>Quote: ""An interactive voice-response system assigned patients on the basis of computer generated block randomization.""</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: The rates of non-completers were 262/7356 (3.6%) and 303/7396 (4.1%) for exenatide group and placebo group, respectively. The rate and cause of adverse events leading to discontinuation of study drugs were almost the same between the groups (43.0% and 45.2% for exenatide group and placebo group, respectively). ITT was performed</p>","Low risk","<p>Quote: ""The events which constitute the principal endpoints of this trial will be adjudicated by the Clinical Events Classification Committee (CEC), coordinated through the Duke Clinical Research Institute (DCRI), which will be comprised of approximately 5-7 physicians and a coordinator.""</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Low risk","<p>The study is judged to be at <b>low risk of bias</b> for all domains for this result</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
8,3,"Change in body weight [kg]","CKD stages 3-5","SUBGROUP_AND_OVERALL","GetGoal studies 2017 - pooled",2017,-0.47,0.46,0,0,0,116,0,0,0,67,0,0,20.166685,-0.47,-1.371583,0.431583,"","Some concerns","<p>Comment: No information were reported on sequence generation and allocation concealment.</p>","Low risk","<p>Comment: All studies included in the pooled analyses were double-blind studies.</p>","Low risk","<p>Quote: ""Analyses of efficacy endpoints were performed using the pooled modified<br>intent-to-treat (mITT) populations.""</p><p>Comment: Slight difference in rate of discontinuation between the intervention and &nbsp;control group (6% and 4%, respectively) but the reasons were balanced. &nbsp;ITT was performed.</p>","Low risk","<p>Comment: ""A data monitoring committee supervised the conduct of the study by an ongoing review of unblinded safety and main efficacy parameters. An allergic reaction adjudication committee (ARAC) performed blinded assessment of potentially allergic or allergic like reactions.""</p>","Some concerns","<p>Comment: Only post-hoc analysis was available, and all prespecified analyses were not reported.</p>","Some concerns","<p>The study is judged to be at some risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
8,3,"Change in body weight [kg]","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,-1.32,0.4694,0,0,0,140,0,0,0,137,0,0,19.505596,-1.32,-2.240007,-0.399993,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
8,3,"Change in body weight [kg]","CKD stages 1-2","SUBGROUP_AND_OVERALL","GetGoal studies 2017 - pooled",2017,-0.5,0.2,0,0,0,0,0,0,0,0,0,0.0081,60.327719,-0.5,-0.891993,-0.108007,"","Some concerns","<p>Comment: No information were reported on sequence generation and allocation concealment.</p>","Low risk","<p>Comment: All studies included in the pooled analyses were double-blind studies.</p>","Low risk","<p>Quote: ""Analyses of efficacy endpoints were performed using the pooled modified<br>intent-to-treat (mITT) populations.""</p><p>Comment: Slight difference in rate of discontinuation between the intervention and &nbsp;control group (6% and 4%, respectively) but the reasons were balanced. &nbsp;ITT was performed.</p>","Low risk","<p>Comment: ""A data monitoring committee supervised the conduct of the study by an ongoing review of unblinded safety and main efficacy parameters. An allergic reaction adjudication committee (ARAC) performed blinded assessment of potentially allergic or allergic like reactions.""</p>","Some concerns","<p>Comment: Only post-hoc analysis was available, and all prespecified analyses were not reported.</p>","Some concerns","<p>The study is judged to be at some risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,4,140,0,0,1,137,0,0,35.875622,3.914286,0.443092,34.578897,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.21969416271073,0,0,1,163,0,0,1,161,0,1.48765385055062,22.300869,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,1,"All-cause death","Dialysis (HD/PD)","SUBGROUP_AND_OVERALL","Idorn 2013",2013,0,0,0,0,0,14,0,0,0,10,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: “Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer-generated randomisation list provided by Novo Nordisk”.</p>","Low risk","<p>Quote: “Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”.</p>","High risk","<p>Comment: &gt;5% lost to follow up with discrepancies between groups.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be <b>at high risk</b> of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,2,151,0,0,0,20,0,0,18.896057,0.690789,0.034328,13.901029,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,1,30,0,0,22.927452,1,0.065532,15.25976,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
9,3,"Cardiovascular death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,1,140,0,0,0,137,0,0,29.853787,2.93617,0.120647,71.457116,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,0,0,0,1,163,0,0,1,161,0,0,39.836935,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,3,"Cardiovascular death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,3,"Cardiovascular death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,1,151,0,0,0,20,0,0,30.309278,0.414474,0.017446,9.847032,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,3,"Cardiovascular death","Dialysis (HD/PD)","SUBGROUP_AND_OVERALL","Idorn 2013",2013,0,0,0,0,0,14,0,0,0,10,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: “Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer-generated randomisation list provided by Novo Nordisk”.</p>","Low risk","<p>Quote: “Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”.</p>","High risk","<p>Comment: &gt;5% lost to follow up with discrepancies between groups.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be <b>at high risk</b> of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
9,8,"Kidney failure","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,7,140,0,0,8,137,0,0,91.285025,0.85625,0.319229,2.296669,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
9,8,"Kidney failure","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,0,0,0,0,163,0,0,1,161,0,0,8.714975,0.329268,0.013513,8.023328,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
9,12,"Fatal or nonfatal stroke","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.41183029808076,0,0,1,163,0,0,1,161,0,1.99326479057881,100,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
9,14,"Withdrawal due to adverse events","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,19,140,0,0,4,137,0,0,23.835501,4.648214,1.623055,13.311869,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
9,14,"Withdrawal due to adverse events","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.42427031354614,0,0,24,163,0,0,8,161,0,2.02854592604883,32.323174,2.96319,1.372071,6.399449,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
9,14,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0.659060248255802,0,0,7,45,0,0,3,31,0,0.434360410830999,18.888509,1.607407,0.450155,5.739705,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
9,14,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0.72978981201317,0,0,17,151,0,0,2,20,0,0.532593169718218,16.788048,1.125828,0.28071,4.51529,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
9,14,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,3,30,0,0,8.164768,0.333333,0.036718,3.026039,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
9,14,"Withdrawal due to adverse events","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
10,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,4,140,0,0,1,137,0,0,35.875622,3.914286,0.443092,34.578897,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,1,"All-cause death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.21969416271073,0,0,1,163,0,0,1,161,0,1.48765385055062,22.300869,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,1,"All-cause death","Dialysis (HD/PD)","SUBGROUP_AND_OVERALL","Idorn 2013",2013,0,0,0,0,0,14,0,0,0,10,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: “Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer-generated randomisation list provided by Novo Nordisk”.</p>","Low risk","<p>Quote: “Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”.</p>","High risk","<p>Comment: &gt;5% lost to follow up with discrepancies between groups.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be <b>at high risk</b> of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,2,151,0,0,0,20,0,0,18.896057,0.690789,0.034328,13.901029,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,1,"All-cause death","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,1,30,0,0,22.927452,1,0.065532,15.25976,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,1,"All-cause death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
10,3,"Cardiovascular death","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
10,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,1,140,0,0,0,137,0,0,29.853787,2.93617,0.120647,71.457116,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
10,3,"Cardiovascular death","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,0,0,0,1,163,0,0,1,161,0,0,39.836935,0.98773,0.062313,15.656611,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
10,3,"Cardiovascular death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0,0,0,0,45,0,0,0,31,0,0,NA,NA,NA,NA,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
10,3,"Cardiovascular death","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0,0,0,1,151,0,0,0,20,0,0,30.309278,0.414474,0.017446,9.847032,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
10,3,"Cardiovascular death","Dialysis (HD/PD)","SUBGROUP_AND_OVERALL","Idorn 2013",2013,0,0,0,0,0,14,0,0,0,10,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: “Patients and control subjects were assigned to receive either liraglutide or pIacebo according to a computer-generated randomisation list provided by Novo Nordisk”.</p>","Low risk","<p>Quote: “Participants, Investigators, and healthcare staff were blinded for the allocated treatment and remained so until the last patient’s last visit”.</p>","High risk","<p>Comment: &gt;5% lost to follow up with discrepancies between groups.</p>","Some concerns","<p>Comment: Objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","High risk","<p>The study is judged to be <b>at high risk</b> of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","3::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.151799707490308,0.000584909318792432,-0.380500654692085,0.0769012397114691,-0.00443876360617602,0.00560858224376088,TRUE,TRUE
10,8,"Severe hypoglycaemia","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,1.00664574233537,0,0,1,140,0,0,0,137,0,1.01333565056193,100,2.93617,0.120647,71.457116,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
10,8,"Severe hypoglycaemia","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,0,0,0,0,163,0,0,0,161,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","8::overall","CD015849_pub2_data","direction_only",FALSE,FALSE,FALSE,-0.0795940690596724,0.00181242281378068,-0.905039386041935,0.74585124792259,-0.00264340793848525,0.0062682535660466,TRUE,TRUE
10,12,"Withdrawal due to adverse events","CKD stages 3-5","SUBGROUP_AND_OVERALL","LIRA-RENAL 2016",2016,0,0,0,0,19,140,0,0,4,137,0,0,23.835501,4.648214,1.623055,13.311869,"","Low risk","<p>Quote: ""Trial patients who met the eligibility criteria at screening were randomised (1:1), using a sponsor-provided telephone- or Web-based randomisation system, to receive (treatment)""</p>","Low risk","<p>Quote: ""Double blind study.""</p>","Low risk","<p>Comment: Discontinuation rates were almost the same between two groups: 35/140 (25%) from the liraglutide group versus 34/137 (24.8%) in the control group. However, the high rate of adverse events in the liraglutide group compared to the control group (13.6% versus 2.9%) might contribute to the attrition bias. ITT was performed.</p>","Some concerns","<p>Comment: No information provided detailing specifically how outcome assessors were kept blind to treatment groups.</p>","Low risk","<p>Comment: All outcomes that were planned in the methods were reported in the results.</p>","Some concerns","<p>The study is judged to raise <b>some concerns </b>in at least one domain for this result, but not to be at high risk of bias for any domain.&nbsp;</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
10,12,"Withdrawal due to adverse events","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0,1.42427031354614,0,0,24,163,0,0,8,161,0,2.02854592604883,32.323174,2.96319,1.372071,6.399449,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
10,12,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024a",2024,0,0.659060248255802,0,0,7,45,0,0,3,31,0,0.434360410830999,18.888509,1.607407,0.450155,5.739705,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
10,12,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Selvarajah 2024b",2024,0,0.72978981201317,0,0,17,151,0,0,2,20,0,0.532593169718218,16.788048,1.125828,0.28071,4.51529,"","Some concerns","<p>Comment: Study was described as randomised, but a method of randomisation was not reported</p>","Low risk","<p>Quote: ""Double blind.""</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
10,12,"Withdrawal due to adverse events","All CKD stages","SUBGROUP_AND_OVERALL","Sivalingam 2024",2024,0,0,0,0,1,30,0,0,3,30,0,0,8.164768,0.333333,0.036718,3.026039,"","Low risk","<p>Quote: ""One person not involved in the study had access to the computer generated random semaglutide/placebo allocation sequence.""</p>","Low risk","<p>Quote: ""Investigators, participants and treating physicians were blinded to treatment allocation.""</p>","Low risk","<p>Quote: ""All participants completed the study and were included into the analysis."" Comment: 54/60 participants were included in the analysis. 28/30 participsnts were included in the interevention group and 26/30 In the control group. However, data were seemed to be reported on the ITT</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
10,12,"Withdrawal due to adverse events","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,0,0,0,40,0,0,0,40,0,0,NA,NA,NA,NA,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","12::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.719612982655567,0.0412770437155713,0.0723470198854709,1.36687894542566,-0.0130204095638513,0.0955744969949939,TRUE,TRUE
10,14,"Acute kidney injury (Hazard ratio)","CKD stages 3-5","SUBGROUP_AND_OVERALL","PIONEER 5 2019",2019,0.6831,1.2234,0,0,0,163,0,0,0,161,0,0,100,1.980006,0.180014,21.778428,"","Low risk","<p>Quote: ""Randomisation was done by use of an interactive web-response system, which allocated dispensing unit numbers for each patient. Randomisation was stratified by background glucose-lowering medication (metformin alone, sulphonylurea with or without metformin, or basal insulin with or without metformin) and renal function (eGFR 45–59 mL/min per 1·73 m² [CKD-EPI stage 3A] or 30–44 mL/min per 1·73 m² [stage 3B]; at least 40% of patients had to be at stage 3B at screening).""</p>","Low risk","<p>Comment: Double-blind study. Patients and site staff were masked to assignment, which was maintained by use of visually identical oral semaglutide and placebo tablets.</p>","Low risk","<p>Comment: ITT was performed, however some participants discontinued.</p>","Low risk","<p>Comment: Outcome assessment was undertaken by an independent event adjudication committee and a central laboratory blinded to the participants allocation assessed blood glucose.</p>","Low risk","<p>Comment: All prespecified and key outcomes were reported.</p>","Low risk","<p>The study is judged to be at low risk of bias in at least one domain for this result.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","14::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,0.781339893860187,0.0591367594965234,0.128152512674325,1.43452727504605,-0.00167705463553482,0.119950573628582,TRUE,TRUE
11,1,"HbA1c  [%]","CKD stages 1-2","SUBGROUP_AND_OVERALL","Ma 2024",2024,0,0,6.91,1.39,0,40,8.92,1.21,0,40,0,0,100,-2.01,-2.581103,-1.438897,"","Low risk","<p>Quote: ""Randomization of patients was performed using a computer-generated random number table. […] This randomization process ensures that the allocation of patients to each group is completely random, reducing potential bias and thereby improving the scientific nature and reliability of the study.""</p>","Some concerns","<p>Comment: Not reported. However, participants and/or investigators could be aware of treatment assigned.</p>","Low risk","<p>Comment: All participants completed the study and were included into the analysis.</p>","Some concerns","<p>Comment: Not reported. However, objective and subjective outcomes were reported.</p>","Some concerns","<p>Comment: Prespecified outcomes were reported. However, major clinical outcomes (death, kidney failure and cardiovascular events) were not reported.</p>","Some concerns","<p>The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015849.pub2/full","10.1002/14651858.CD015849.pub2","1::overall","CD015849_pub2_data","significance_only",TRUE,TRUE,FALSE,-0.172262845924745,-0.000476660290895169,-0.287859706818699,-0.056665985030792,-0.00671701488465776,0.00576369430286742,TRUE,TRUE
